Table 1.

Percentage of cells in G0-G1 phase of cell cycle (A) and percentage of apoptotic cells (B) in sensitive and resistant sublines after treatment with AMN107 and imatinib at equipotent doses

Exposure time (h)KBM5 (∼IC90)
KBM5-STI571R1.0 (∼IC60)
KBM7 (∼IC90)
KBM7-STI571R1.0 (∼IC80)
0Imatinib (1,000 nmol/L)AMN107 (25 nmol/L)0Imatinib (8,000 nmol/L)AMN107 (3,000 nmol/L)0Imatinib (1,000 nmol/L)AMN107 (25 nmol/L)0Imatinib (4,000 nmol/L)AMN107 (160 nmol/L)
A. Percentage of cells in G0-G1
2432.073.975.725.943.063.930.325.732.634.954.859.7
4832.187.488.427.541.055.729.035.541.529.548.049.5
7224.576.383.329.652.060.826.536.836.634.345.148.9
B. Percentage of apoptotic cells
244.85.35.69.011.417.211.524.824.728.737.936.6
483.68.37.98.313.729.79.244.740.628.849.061.1
723.814.717.610.315.130.015.059.453.525.953.867.4
  • NOTE: Propidium iodide staining and flow cytometry were used to determine cell cycle contents. PhiPhiLux G1D2 kit was used to detect caspase-3 activity by flow cytometry.